Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
NCT03234556 · View on ClinicalTrials.gov ↗
Study Summary
This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific antigen. Systematic random biopsy and MRI-US fusion biopsy may work better in improving the accuracy of prostate cancer detection.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Biopsy of Prostate
- DIAGNOSTIC_TEST Magnetic Resonance Imaging
- DIAGNOSTIC_TEST MRI Ultrasound Fusion Guided Biopsy
Study Locations (4)
California
- USC / Norris Comprehensive Cancer Center — Los Angeles
Maryland
- University of Maryland — Baltimore
Michigan
- Henry Ford Hospital Vattikuti Urology Institute — Detroit
New York
- Memorial Sloan-Kettering Cancer Center — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2028-05-23 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03234556
The ClinicalTrials.gov registry entry for NCT03234556 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 412 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Health Status Unknown appearing as the primary indexed condition, and to 4 interventions — of which Laboratory Biomarker Analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03234556 reports 4 study locations spanning 4 distinct geographic areas — top geographies include California, Maryland, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03234556 about?
NCT03234556 is a clinical study titled "Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA". This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific antigen. Systematic random biopsy and MRI-US fusion biopsy may work better i...
What is the current status of trial NCT03234556?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 288 participants. The study started on 2017-09-25. Estimated completion is 2028-05-23.
What conditions does trial NCT03234556 study?
This clinical trial studies the following conditions: Health Status Unknown, Elevated PSA. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03234556?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Biopsy of Prostate (PROCEDURE), Magnetic Resonance Imaging (DIAGNOSTIC_TEST), MRI Ultrasound Fusion Guided Biopsy (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03234556?
This trial is sponsored by University of Southern California, which has 412 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03234556 being conducted?
This trial has 4 study locations across California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.